2026-10-14 · By WeightFAQ Staff

Why GLP-1 Weight-Regain Forecasts Disagree

Will all the weight return after a GLP-1 medication stops, or will some of the benefit last? Two peer-reviewed reviews published in 2026 offer different long-term projections. That disagreement matters, especially if you are deciding whether a treatment fits your budget and long-term care plans. But it does not mean researchers disagree about everything: substantial regain after stopping is a consistent finding.

The distinct lesson from comparing these papers is that a forecast beyond a study’s follow-up is not the same thing as a measured outcome. A straight-line projection and a slowing recovery curve can fit a similar short-term story yet lead to different destinations. Neither gives an individual patient an expiry date for their weight loss.

The two forecasts are answering different questions

In January, a systematic review in The BMJ examined 37 studies of weight change after stopping weight-management medication. Across the included medications, the average monthly regain rate was about 0.4 kilograms. Its model projected a return to baseline weight approximately 1.7 years after cessation. This was a broad medication review, not a result restricted to one modern GLP-1 drug or one patient population.

In March, an eClinicalMedicine review took a different approach to GLP-1 receptor agonists, including tirzepatide in its evidence base. It identified 48 relevant studies but used six randomized trials, with 3,236 participants, for its nonlinear meta-regression. At one year after cessation, the model estimated that approximately 60% of the weight lost during treatment had returned. Beyond 52 weeks, it extrapolated a slowing curve toward a plateau of about 75% of the lost weight regained.

These numbers are not interchangeable. The BMJ estimate describes kilograms per month across a broader drug evidence base. The nonlinear estimate describes the proportion of prior weight loss regained in a selected trial set. Different inclusion criteria, treatments, starting losses, and mathematical assumptions all affect the comparison. The papers do not constitute a head-to-head experiment testing which forecast is correct.

A plateau is a prediction, not a promise

The nonlinear review explicitly states that trajectories beyond 52 weeks were extrapolated. Its estimated plateau was 75.3%, with a 95% confidence interval of 68.9% to 81.6%. That interval describes uncertainty in the modeled estimate; it does not capture every possible future outcome for every person.

For illustration only, imagine someone lost 20 kilograms during treatment. Regaining 75% of that loss would mean 15 kilograms returned and 5 remained off. It would not mean gaining 75% of their body weight. This arithmetic explains the denominator, not what will happen to someone who stops a prescription.

Likewise, a projected return to baseline in 1.7 years is not proof that everyone regains everything at that point. A model extends patterns beyond observations under assumptions about how the future behaves. Longer follow-up could strengthen, weaken, or change either forecast. The useful conclusion is uncertainty about the eventual destination, alongside much stronger evidence that stopping commonly brings substantial regain.

What was actually observed in a withdrawal study?

The STEP 1 trial extension provides a concrete check against treating models as settled facts. One year after withdrawal of semaglutide 2.4 milligrams and the structured lifestyle intervention, participants had regained, on average, about two-thirds of their previous weight loss. Cardiometabolic improvements also tended back toward baseline.

That is a measured result over a defined follow-up period. It still has limits: an extension sample is not every patient, the lifestyle intervention stopped too, and the observation does not establish what happens indefinitely. Nor does it tell us that tapering, a particular diet, or a lower maintenance dose would reliably prevent regain. Those are separate clinical questions requiring their own evidence.

The newer nonlinear review also assessed most included studies as having moderate risk of bias. Its modeling subset was much smaller than its full study inventory. Counting 48 studies should not be mistaken for having 48 independent long-term trials confirming a lasting plateau.

Use the uncertainty to improve the appointment, not to change your dose

Before starting medication, ask what ongoing treatment and follow-up would look like if it helps. If you already take it, bring up foreseeable coverage changes or side effects early. A planning conversation can cover access, appropriate alternatives, how your clinician would monitor weight and relevant health markers, and when reassessment would be needed if treatment changes.

Do not turn either paper into a self-directed taper or a reason to continue despite a medical problem. Weight is only one part of the decision; diabetes management, other conditions, treatment tolerability, and your preferences matter. A prescriber can distinguish an elective change from a situation requiring prompt medical attention.

Our GLP-1 overview explains the treatment context, while our weight-loss maintenance guide covers everyday habits that support ongoing care. Neither a research forecast nor a lifestyle checklist guarantees that regained weight can be avoided.

The bottom line is more useful than either headline alone: plan for the possibility of substantial regain, but do not mistake a group-level projection for your personal future. The disagreement between the 2026 models is a reason to ask better follow-up questions, not a reason to blame yourself or assume that the long-term science is finished.

Browse evergreen Weight Loss Guides →